Cadrenal Therapeutics, Inc.
$5.25
▼
-4.08%
2026-04-21 06:19:00
www.cadrenal.com
NCM: CVKD
Explore Cadrenal Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$13.09 M
Current Price
$5.25
52W High / Low
$17.5 / $4.21
Stock P/E
—
Book Value
$1.17
Dividend Yield
—
ROCE
-491.51%
ROE
-2.6%
Face Value
—
EPS
$-6.64
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
—
Beta
1.55
Debt / Equity
—
Current Ratio
2.72
Quick Ratio
2.72
Forward P/E
-1.22
Price / Sales
—
Enterprise Value
$7.92 M
EV / EBITDA
-0.59
EV / Revenue
—
Rating
Strong Buy
Target Price
$27.67
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Alpha Tau Medical Ltd. | $8.11 | — | $706.72 M | — | -44.45% | -61% | $8.6 / $2.5 | $0.88 |
| 2. | MeiraGTx Holdings plc | $10.53 | — | $857.63 M | — | -86.95% | -3.68% | $11.85 / $4.55 | $-0.07 |
| 3. | Seer, Inc. | $1.99 | — | $112.84 M | — | -27.82% | -25.08% | $2.41 / $1.65 | $4.61 |
| 4. | Zura Bio Limited | $5.37 | — | $491.42 M | — | -74.11% | -52.49% | $7.44 / $0.98 | $1.38 |
| 5. | Codexis, Inc. | $2.62 | — | $235.35 M | — | -31.3% | -74.88% | $3.87 / $0.96 | $0.56 |
| 6. | Novavax, Inc. | $8.67 | 3.2 | $1.41 B | — | 76.84% | -117.16% | $11.97 / $5.8 | $-0.79 |
| 7. | Ultragenyx Pharmaceutical Inc. | $25.06 | — | $2.39 B | — | -46.6% | -6.08% | $42.37 / $18.29 | $-0.83 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -3.07 M | -2.73 M | -3.73 M | -3.93 M | -4.28 M | — |
| Net Profit | -3.04 M | -2.69 M | -3.67 M | -3.85 M | -4.19 M | — |
| EPS in Rs | -1.21 | -1.07 | -1.46 | -1.53 | -1.67 | -2.18 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | — |
| Operating Profit | -13.46 M | -10.96 M | -7.63 M | — |
| Net Profit | -13.24 M | -10.65 M | -8.36 M | — |
| EPS in Rs | -5.28 | -4.25 | -3.33 | — |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 4.33 M | 10.12 M | 8.52 M | 0.78 M |
| Total Liabilities | 1.59 M | 2.68 M | 0.83 M | 6.33 M |
| Equity | 2.74 M | 7.44 M | 7.69 M | -5.55 M |
| Current Assets | 4.32 M | 10.11 M | 8.49 M | 0.73 M |
| Current Liabilities | 1.59 M | 2.68 M | 0.83 M | 1.33 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating CF | -12.6 M | -7.36 M | -3.53 M |
| Investing CF | -0.01 M | -0.01 M | -0 M |
| Financing CF | 6.6 M | 8.98 M | 11.9 M |
| Free CF | -12.61 M | -7.36 M | -3.53 M |
| Capex | -0.01 M | -0.01 M | -0 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue Growth % | — | — | — |
| Earnings Growth % | -24.28% | -27.45% | — |
| Profit Margin % | — | — | — |
| Operating Margin % | — | — | — |
| Gross Margin % | — | — | — |
| EBITDA Margin % | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-08-20 | 1:0.0666667 |